Samuel Okoh, MD
Nephrology · Hartsville, SCNPI 1730381252
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (53.9%), food and beverage and education — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 67.9% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2024 at $2,282 and has fallen 88.0% since, to $275 in 2025.
Across 53 payments — averaging $59.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Amgen$421
- Otsuka America Pharmaceutical, Inc.$267
- GSK$77
- Travere Therapeutics, Inc.$54
- Mallinckrodt Hospital Products Inc.$33
- plus $161 from 6 others
What the payments were for
- Travel & lodging$1,70154%
- Food & beverage$1,39744%
- Education$572%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 5 | $2,142 |
| Amgen(2 entities) | 22 | $421 |
| Otsuka America Pharmaceutical, Inc. | 9 | $267 |
| GSK | 1 | $77 |
| Travere Therapeutics, Inc. | 5 | $54 |
| Mallinckrodt Hospital Products Inc. | 2 | $33 |
| Bayer | 2 | $33 |
| Novo Nordisk | 1 | $32 |
| AstraZeneca | 2 | $31 |
| Johnson & Johnson | 2 | $26 |
| Fresenius USA Marketing, Inc. | 1 | $24 |
| Ardelyx, Inc. | 1 | $16 |
How this compares
$3,155 in reported general payments places this provider in the 60th percentile of 180 nephrology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 847 | $558,418 |
| JynarqueTolvaptan | 22 | $424,691 |
| VelphoroSucroferric Oxyhydroxide | 102 | $200,482 |
| JardianceEmpagliflozin | 260 | $193,331 |
| AuryxiaFerric Citrate | 77 | $148,345 |
| Sevelamer Carbonate | 187 | $22,295 |
| DapagliflozinDapagliflozin Propanediol | 36 | $19,425 |
| Lanthanum Carbonate | 28 | $16,606 |
| EliquisApixaban | 27 | $15,846 |
| JanuviaSitagliptin Phosphate | 24 | $14,233 |
| OzempicSemaglutide | 16 | $13,262 |
| ProcritEpoetin Alfa | 14 | $11,546 |
| MyrbetriqMirabegron | 18 | $8,185 |
| VeltassaPatiromer Calcium Sorbitex | 18 | $7,014 |
| Nifedipine ErNifedipine | 73 | $2,078 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $31 | $558,418847 claims |
| Otsuka America Pharmaceutical, Inc.Jynarque | $267 | $424,69122 claims |
| Fresenius USA Marketing, Inc.Velphoro | $24 | $200,482102 claims |
| Novo NordiskOzempic | $32 | $13,26216 claims |
| Johnson & JohnsonProcrit | $26 | $11,54614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 180 nephrology providers in South Carolina.
Other nephrology in Hartsville
- Jessica ColemanBeaufort$930K
- Moustafa MoustafaOrangeburg$616K
- Harold SzerlipCharleston$229K
- Barry GorlitskyGreenville$195K
- Blake ShustermanGreenville$66K
- Martin WebbBeaufort$66K
- Mohammed AlzubaidiSumter$54K
- Joshua LipschutzCharleston$44K
- Renee EllisColumbia$40K
- Charles BunkeCharleston$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.